Astellas defends Xtandi patent as court rejects generics’ appeal

Court of Appeal backs Astellas in UK patent fight over prostate cancer drug | Generics’ challenge fails as judges warn on expert evidence and hindsight bias | Court urges caution when instructing expert witnesses in obviousness cases.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Orrick lands five-member M&A team in Paris

18 May 2026 A high-profile Paris-based partner and four others join the firm, bringing experience across M&A, venture capital and life sciences-focused transactions.

Europe

IP in the deal room: The risks that bite before, during and after closing

7 May 2026 Experts from Johnson & Johnson and Novartis took the stage at INTA to share the pitfalls lurking inside mergers, acquisitions and spin-offs and what in-house counsel can do about them.

Europe

Five generations at work: How teams are bridging the gap

6 May 2026 Panellists at INTA share how workplaces can bridge generational divides and why those differences may be a team’s biggest strengths.